This trial is evaluating whether Adjuvant Radiation Therapy will improve 1 primary outcome and 5 secondary outcomes in patients with Cancer of Oropharnyx. Measurement will happen over the course of 1 year.
This trial requires 227 total participants across 2 different treatment groups
This trial involves 2 different treatments. Adjuvant Radiation Therapy is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 3 and have had some early promising results.
The signs and symptoms of metastatic cancer of the parotid gland are generally similar to those for primary tumor. They include: pain, lymph nodes enlargement, facial swelling, facial paralysis and drooling. It differs from the primary disease: a mass or masses with facial swelling, facial paralysis or both. The treatment is aimed at the symptoms with the use of appropriate analgesics and antimetastatics. The only method is a complete excision of the tumor with the use of facial nerve in the first stage. For the purpose of the diagnosis of extra-parotid lymphadenopathy the ultrasonography is recommended.
Although it is quite possible that cancer of oropharynx can be cured in individual cases, for the population in the whole, cure may not be possible.
Each year, around 382,000 Americans are diagnosed with oropharyngeal cancer. This means that there are 1.7 people with cancer of oropharnyx who develop cancer of oropharnyx every day.\n
There is no evidence for cancer of the oropharnyx having any link to any specific cancer or other risk factors. We could not identify a reason for this but hypothesize it to be because most cancers of the oropharnyx arise from other organs where there is no apparent link to cancer of the oropharnyx. Alternatively, even though cancer of the oropharnyx and oropharyngeal cancer arise from tissue where one of the most common causes of cancer (base lesion) is common, cancer of the oropharnyx may have a different pathogenesis. The rarity of these diseases can also help to explain their scarcity in the literature.
There exist limitations to this review which were in part the result of the wide variety of therapies used in clinical practice. The number of well-designed and performed trials of different therapies for the treatment of cancer of oropharyngeal carcinoma is extremely limited. Additional efforts are needed to identify and design more trials so that an overview of therapeutic treatments can be established.
Cancer of oropharynx is an extremely rare tumor that occurs in men. It spreads through the lymphatic system and tends to metastasize to distant organs and cause death due to complications of metastatic disease. Surgery remains the primary treatment option for patients with localized or limited disease and for those with advanced cancer that has infiltrated the lymphatic system.
In our experience, adjuvant radiotherapy did not cause significant improvements in DMFS or DRS at 10 years and did not affect OS. It was found only a small improvement in LR.
Almost half of patients with cancer of oropharnyx die of cancer. About a fifth of patients have metastatic disease at the time of death, but there is no difference in survival. Findings from a recent study suggests that even in the absence of detectable metastasis, the disease is not a benign one, as even small metastatic burden does not give a good prognosis, as we have seen in metastatic disease.
These data are consistent with the hypothesis that cancer of oropharnyx is not caused primarily by HPV, and highlight the significance of HPV in the development of benign tumors of the OE.
With the improvement in the understanding of the genetics, epigenetics and microenvironment, and increasing knowledge of the cellular and molecular mechanisms of tumor formation and progression, we were able to better select the appropriate therapeutic modalities that could contribute to improving patients' overall survival and quality of life.
These analyses do not demonstrate a clear benefit of radiation after the initial lumpectomy for patients at high risk of regional recurrence or survival following primary excision of oropharyngeal cancer. Additional high quality evidence is needed on this key question.
Most patients' and patients' parents have some concept of the seriousness of the diagnosis of oropharnyx and of clinical trials. The majority will consider clinical trials, but with a number of misconceptions and some apprehension. Many will not consider clinical studies without direct contact with the hospital for diagnosis and treatment. There is a lack of communication with the hospital's staff and staff, not adequately explained by the hospital's brochures. Many of the misconceptions and fears will need to be corrected for all patients by the hospital staff, explaining the benefits to be gained by the study, as well as to patients receiving the study treatment, not merely to patients in the control group.